A recent study involving a previously unstudied gene known as Rfx6 has shown how this gene is necessary for cells to differentiate into insulin-producing beta cells and other cells in the pancreas. This study was led by Michael German, MD, Diabetes Center Clinical Director and the Justine K. Schreyer Endowed Chair in Diabetes Research, and his colleague Constantin Polychronakos, MD, of McGill University.
It is hard to believe that we are just days away from the end of the decade, and nearly ten years since the founding of the UCSF Diabetes Center. I am grateful for the progress we continue to make toward preventing, treating and ultimately curing diabetes.
Within the last year, one of our type 1 diabetes clinical trials involving an effective cancer drug concluded. Results published in November 2009 in the New England Journal of Medicine (NEJM)shows that anti-CD20 (FDA approved and marketed as Rituxan) has been shown to be effective in new onset diabetes by slowing down the progression of the disease.
Three Diabetes Center affiliated researchers are featured in a recent issue of Forefront magazine, a publication of the American Diabetes Association (ADA). Robert Farese Jr., MD, a senior scientist at the UCSF Gladstone Institute of Cardiovascular Disease, is studying the biology of fat storage.
In conjunction with last month's National Diabetes Month, KPIX CBS 5 in San Francisco spotlighted the work of the Diabetes Center at UCSF. On November 10th, CBS 5 Healthwatch Doctor Kim Mulvihill, MD discussed an experimental drug called anti-CD3 and how it may stop beta cell destruction in type 1 diabetes.
Forbes magazine’s annual feature on the Most Powerful People included UCSF Chancellor Susan Desmond-Hellmann, MD, MPH, among the world’s seven Most Powerful Innovators. The story appearing in the November 30 issue called Desmond-Hellmann a “hero to legions of cancer patients” for her role in the development of the cancer drugs Avastin and Herceptin.
Last month, the California Institute of Regenerative Medicine (CIRM) awarded a Diabetes Disease Team Award to Novocell, Inc., a San Diego-based stem cell engineering biotech, and the UCSF Diabetes Center, led by Jeffrey Bluestone, PhD, Michael German, MD, Matthias Hebrok, PhD, and Qizhi Tang, PhD. Called the "dream team" by CIRM working group reviewers, this group's
The body's immune system is supposed to "tolerate" itself and distinguish "self" from "non-self." Autoimmune diseases such as type 1 diabetes result from the breakdown of this system, causing immune cells to attack and destroy insulin-producing beta cells or "self."
After living with type 1 diabetes for 33 years, Ken Reynolds feels like a new person with a much better quality of life -- thanks to an islet transplant he received at UCSF last January. Diagnosed with diabetes as a child, Ken began to experience severe hypoglycemic unawareness ten years ago.
A new study, Assessing the Value of Diabetes Education, has shown that healthcare costs for the serious consequences of diabetes are significantly lower for people who have been referred to a diabetes education program.
The UCSF Center for Vulnerable Populations (CVP) at San Francisco General Hospital (SFGH) continues to receive recognition for its innovative research that advances health communication to prevent and treat chronic diseases in patients at risk.
In the July issue of Nature , a team of researchers at UCSF, Jerusalem and Portugal announced that they have identified a gene, Chd1, that is required for embryonic stem cells to keep their all-purpose, pluripotent state.
President Barack Obama awarded stem cell faculty member Jeremy Reiter, MD, PhD a Presidential Early Career Award for Scientists and Engineers. Dr. Reiter was one of twelve awardees selected by the President’s White House Office of Science and Technology.